Inhibitor Therapeutics

OverviewSuggest Edit

Inhibitor Therapeutics (formerly known as HedgePath Pharmaceuticals) is a pharmaceutical company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. It develops SUBA-Itraconazole, a patented, oral formulation of the currently marketed, anti-fungal drug, Itraconazole, for treatment of prostate and lung cancers.
TypePublic
Founded1992
HQTampa, US
Websiteinhibitortx.com

Latest Updates

Employees (est.) (Mar 2019)2(-33%)
Revenue (FY, 2018)$0
Share Price (Nov 2020)$0
Cybersecurity ratingAMore

Key People/Management at Inhibitor Therapeutics

Nicholas Virca

Nicholas Virca

President and Chief Executive Officer
Robert D. Martin

Robert D. Martin

Director
Garrison Hasara

Garrison Hasara

Chief Financial Officer, Treasurer, Corporate Secretary, Chief Compliance Officer
Stefan J. Cross

Stefan J. Cross

Director
Amy McCord

Amy McCord

Vice President, Regulatory Affairs
R. Dana Ono

R. Dana Ono

Director
Show more

Inhibitor Therapeutics Office Locations

Inhibitor Therapeutics has an office in Tampa
Tampa, US (HQ)
4830 W Kennedy Blvd #600Tampa
Show all (1)

Inhibitor Therapeutics Financials and Metrics

Inhibitor Therapeutics Revenue

USD

Net income (Q2, 2020)

(314.9k)

EBIT (Q2, 2020)

(315.0k)

Market capitalization (16-Nov-2020)

14.0m

Closing stock price (16-Nov-2020)

0.0

Cash (30-Jun-2020)

137.3k
Inhibitor Therapeutics's current market capitalization is $14 m.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

General and administrative expense

817.3k1.5m2.3m4.4m2.9m1.9m1.5m

R&D expense

1.1m2.4m1.7m2.6m2.2m2.6m1.2m

Operating expense total

1.9m3.9m3.9m7.0m5.1m4.6m2.7m
Quarterly
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

General and administrative expense

161.6k185.2k571.1k609.7k491.4k600.4k612.0k724.5k1.0m278.7k247.6k500.8k355.5k400.1k594.8k331.9k318.5k288.0k262.4k

R&D expense

25.3k1.9m167.0k313.0k300.3k601.7k582.5k605.5k720.3k440.8k433.5k674.0k528.9k775.4k196.8k303.6k364.4k97.5k52.7k

Operating expense total

186.9k2.1m738.1k922.7k791.7k1.2m1.2m1.3m1.7m719.4k681.2k1.2m884.4k1.2m791.6k635.5k682.9k385.4k315.0k
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(1.8m)(4.0m)(3.9m)(7.0m)(5.1m)(4.6m)(2.7m)

Accounts Payable

46.6k61.3k151.0k(153.7k)293.4k(785.0)(270.4k)

Cash From Operating Activities

(1.2m)(1.3m)(2.3m)(3.8m)(2.9m)(3.7m)(2.7m)

Short-term Borrowings

(105.2k)
Show all financial metrics

Inhibitor Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Inhibitor Therapeutics Online and Social Media Presence

Embed Graph

Inhibitor Therapeutics News and Updates

HedgePath Pharmaceuticals Announces Notice of Allowance with Additional Claims Governing the Use of SUBA®-Itraconazole for the Treatment of Lung Cancer

TAMPA, Fla., May 29, 2019 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders,...

HedgePath Pharmaceuticals Announces Notice of Allowability of U.S. Patent Application Regarding Treatment of Prostate Cancer

TAMPA, Fla., May 6, 2019 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative therapeutics to inhibit the progression of cancerous and non-cancerous proliferation...

W. Mark Watson Elected as Chairman of the Board of HedgePath Pharmaceuticals

TAMPA, Fla., April 15, 2019 /PRNewswire/ -- HedgePath Pharmaceuticals, Inc. (OTCQB: HPPI), a pharmaceutical development company focused on discovering, developing and ultimately commercializing innovative therapies for patients with cancer and non-cancerous proliferation disorders,...

Inhibitor Therapeutics Frequently Asked Questions

  • When was Inhibitor Therapeutics founded?

    Inhibitor Therapeutics was founded in 1992.

  • Who are Inhibitor Therapeutics key executives?

    Inhibitor Therapeutics's key executives are Nicholas Virca, Robert D. Martin and Garrison Hasara.

  • How many employees does Inhibitor Therapeutics have?

    Inhibitor Therapeutics has 2 employees.

  • Who are Inhibitor Therapeutics competitors?

    Competitors of Inhibitor Therapeutics include Xilio Therapeutics, Sareum Holdings and Alligator Bioscience.

  • Where is Inhibitor Therapeutics headquarters?

    Inhibitor Therapeutics headquarters is located at 4830 W Kennedy Blvd #600Tampa, Tampa.

  • Where are Inhibitor Therapeutics offices?

    Inhibitor Therapeutics has an office in Tampa.

  • How many offices does Inhibitor Therapeutics have?

    Inhibitor Therapeutics has 1 office.